All In Biotech

Drug Trial Radar · NCT06973681

A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Safety, Tolerability, PK/PD Profile, and Efficacy of Multiple Doses of BGM0504 Injection in Overweight or Obese Subjects Without Diabetes

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Oct 13, 2023

Primary completion

Sep 13, 2024

Study completion Sep 13, 2024

Sponsor

Sponsor type
Industry
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.

Conditions

  • Overweight or Obesity

Interventions

  • BGM0504Drug

    Administered SC

  • BGM0504Drug

    Administered SC

  • BGM0504Drug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weightTime frame: Week 0 to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Xiangya Hospital of Central South University

    Changsha, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.